文献速递免疫规划慢病防控与筛查

带状疱疹疫苗疗效与安全性比较:网状Meta分析

The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis.
PubMed 文献 · Vaccine · 2019-04-11

该网状Meta分析基于随机对照试验证据,比较了佐剂重组带状疱疹疫苗(RZV)与带状疱疹减毒活疫苗(ZVL)的疗效与安全性。结果显示,在≥60岁和≥70岁成人中,RZV预防带状疱疹(HZ)和带状疱疹后神经痛(PHN)的效力显著高于ZVL;RZV接种后反应原性更高,但严重不良事件(SAE)无显著差异。

要点

  • 在≥60岁成人中,RZV预防HZ的疫苗效力(VE)为0.92,ZVL为0.51。
  • 在≥70岁成人中,RZV预防PHN的VE为0.89,ZVL为0.67。
  • RZV接种后注射部位和全身反应较ZVL多数剂型更常见,但SAE无显著差异。

核心结论

  • 在≥60岁成人中,RZV预防HZ和PHN的效力显著高于ZVL。
  • RZV接种后反应原性更高,但SAE与ZVL无统计学显著差异。

研究设计与样本

  • 基于随机对照试验证据的网状Meta分析,纳入RZV和ZVL不同剂型。
  • 疗效结局采用固定效应频率学网状Meta分析,安全性和反应原性采用固定和随机效应。
  • 疫苗效力分析按年龄分层。

主要发现

  • ≥60岁成人中,RZV预防HZ的VE为0.92(95%CI:0.88,0.94),ZVL为0.51(95%CI:0.44,0.57)。
  • ≥70岁成人中,RZV预防HZ的VE为0.91(95%CI:0.87,0.94),ZVL为0.37(95%CI:0.25,0.48)。
  • ≥60岁成人中,RZV预防PHN的VE为0.89(95%CI:0.70,0.96),ZVL为0.66(95%CI:0.48,0.78)。
  • ≥70岁成人中,RZV预防PHN的VE为0.89(95%CI:0.69,0.96),ZVL为0.67(95%CI:0.44,0.80)。
  • RZV的注射部位和全身反应显著多于ZVL多数剂型和安慰剂,但RZV与ZVL任何剂型或安慰剂之间SAE无统计学显著差异。

临床怎么用

  • 在≥60岁成人中,RZV可作为预防HZ和PHN的优先选择,因其效力显著高于ZVL。
  • 接种RZV前应告知受种者反应原性可能较高,但SAE风险与ZVL无显著差异。

局限性

  • 疗效结局因数据有限仅采用固定效应模型。
  • 纳入研究间反应原性定义和数据收集程序存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We estimated the relative efficacy and safety of vaccines for prevention of herpes zoster (HZ) using network meta-analysis (NMA) based on evidence from randomized controlled trials. METHODS: A systematic literature review evaluated two different HZ vaccines: adjuvanted recombinant zoster vaccine (RZV) and zoster vaccine live (ZVL), with different formulations assessed. Detailed feasibility assessment indicated that a NMA was feasible for efficacy (incidence of HZ and postherpetic neuralgia [PHN]) and safety (serious adverse events [SAE] and reactogenicity [injection-site reactions, systemic reaction]) outcomes. Primary analyses included frequentist NMAs with fixed effects for efficacy outcomes, due to limited data availability, and both fixed and random effects for safety and reactogenicity outcomes. As age is a known effect modifier of vaccine efficacy (VE), VE analyses were stratified by age. RESULTS: RZV demonstrated significantly higher HZ efficacy than ZVL in adults ≥60 years of age (YOA) (VERZV = 0.92 (95% confidence interval [95%CI]: 0.88, 0.94), VEZVL = 0.51 (95%CI: 0.44, 0.57)) and adults ≥70 YOA (VERZV = 0.91 (95%CI: 0.87, 0.94), VEZVL = 0.37 (95%CI: 0.25, 0.48)). Similarly, RZV demonstrated significantly higher PHN efficacy than ZVL in adults ≥60 YOA (VERZV = 0.89 (95%CI: 0.70, 0.96), VEZVL = 0.66 (95%CI: 0.48, 0.78)) and adults ≥70 YOA (VERZV = 0.89 (95%CI: 0.69, 0.96), VEZVL = 0.67 (95%CI: 0.44, 0.80)). RZV was associated with significantly more injection-site and systemic reactions compared to most formulations of ZVL and placebo, however definitions and data collection procedures differed across the included studies. There were no statistically significant differences found between RZV and any formulation of ZVL or placebo for SAEs. CONCLUSION: RZV is significantly more effective in reducing HZ and PHN incidence in adults ≥60 YOA, compared with ZVL. As anticipated with an adjuvanted vaccine, RZV results in more reactogenicity following immunization. No differences in SAEs were found between RZV and ZVL.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. McGirr A, Widenmaier R, Curran D, et al. The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis. Vaccine. 2019. PMID: 30982636. doi:10.1016/j.vaccine.2019.04.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。